Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia

Atherosclerosis. 2007 Dec;195(2):e100-7. doi: 10.1016/j.atherosclerosis.2007.06.030. Epub 2007 Aug 9.

Abstract

Objective: To investigate the lipotropic action of betaine on plasma lipoproteins and tissue lipids.

Methods and results: Adult mice, wild type (+/+) or heterozygous (+/-) for a disruption of the methylenetetrahydrofolate reductase (Mthfr) gene, were supplemented with betaine for 1 year and compared with mice on control diets. Outcome measures were plasma homocysteine and lipoprotein levels, aortic and liver morphology, and liver staining for 3-nitrotyrosine (oxidative stress marker) and Apolipoprotein A-I (ApoA-I). We also investigated short-term effects of supplemental betaine on plasma lipoproteins in Mthfr +/+ and +/- mice. Both genotypes showed significantly lower plasma homocysteine after long-term betaine supplementation, and lower plasma triglycerides and higher HDL-cholesterol after both short- and long-term betaine. Lipid accumulation in liver and aortic wall tended to be lower in Mthfr+/+ compared to Mthfr+/- mice and in betaine-supplemented compared to unsupplemented mice. Nitrotyrosine staining was higher and ApoA-I staining was lower in livers of Mthfr+/- compared to Mthfr+/+ mice. Betaine did not affect staining of nitrotyrosine but increased ApoA-I staining. A significant negative correlation was observed between plasma homocysteine and liver ApoA-I.

Conclusions: Mild MTHFR deficiency in mice is associated with increased risk for atherosclerotic disease. Betaine has a lipotropic effect, which is associated with a reduction in homocysteine, an increase in ApoA-I and an amelioration of the atherogenic risk profile.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Genetically Modified
  • Aorta / pathology
  • Apolipoprotein A-I / drug effects*
  • Betaine / pharmacology*
  • Cholesterol
  • Disease Models, Animal
  • Fatty Liver / pathology
  • Homocysteine / drug effects*
  • Hyperhomocysteinemia / drug therapy*
  • Immunohistochemistry
  • Lipotropic Agents / pharmacology*
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Mice
  • Zeit
  • Triglycerides / blood
  • Tyrosine / analogs & derivatives
  • Tyrosine / analysis

Substances

  • Apolipoprotein A-I
  • Lipotropic Agents
  • Triglycerides
  • Homocysteine
  • 3-nitrotyrosine
  • Betaine
  • Tyrosine
  • Cholesterol
  • Methylenetetrahydrofolate Reductase (NADPH2)